Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanofi-GSK Monovalent (B.1.351) COVID-19 Vaccine in Kidney Transplant Recipients
NCT05518487Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of monovalent [B.1.351] CoV2 preS dTM-AS03 in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2023; status: completed.
02
Drugs
monovalent [B.1.351] CoV2 preS dTM-AS03
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05518487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518487.